NOD2 and breast neoplasm: Polymorphysms of TLR4 are linked to different outcomes in patients with breast tumors, while other immune-related loci (e.g., TNF-α, NF-κB, Janus kinases (JAK)/STAT proteins, Fc receptors FcγRIII (CD16), nucleotide-binding oligomerization domain-containing protein 2 (NOD2), autophagy related protein 16 (ATG16) and inflammasome pathway proteins) have also been linked to differences in the response to immunotherapy against cancer.